Empyrean Capital Partners Lp buys $88,090,484 stake in Pfizer (PFE)

Pfizer (PFE) : Empyrean Capital Partners Lp scooped up 582,810 additional shares in Pfizer during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 2,518,310 shares of Pfizer which is valued at $88,090,484.Pfizer makes up approximately 5.66% of Empyrean Capital Partners Lp’s portfolio.

Other Hedge Funds, Including , Greenwich Wealth Management boosted its stake in PFE in the latest quarter, The investment management firm added 889 additional shares and now holds a total of 134,914 shares of Pfizer which is valued at $4,719,292. Pfizer makes up approx 1.04% of Greenwich Wealth Management’s portfolio.Sound Shore Management Inc Ct boosted its stake in PFE in the latest quarter, The investment management firm added 176,245 additional shares and now holds a total of 4,459,240 shares of Pfizer which is valued at $158,035,466. Pfizer makes up approx 2.73% of Sound Shore Management Inc Ct’s portfolio.Hyman Charles D boosted its stake in PFE in the latest quarter, The investment management firm added 8,233 additional shares and now holds a total of 130,724 shares of Pfizer which is valued at $4,632,859. Pfizer makes up approx 0.69% of Hyman Charles D’s portfolio.

Pfizer closed down -0.12 points or -0.34% at $34.68 with 1,59,21,155 shares getting traded on Thursday. Post opening the session at $34.73, the shares hit an intraday low of $34.61 and an intraday high of $34.94 and the price fluctuated in this range throughout the day.Shares ended Thursday session in Red.

On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.

Many Wall Street Analysts have commented on Pfizer. Shares were Reiterated by Jefferies on Jun 20, 2016 to “Buy” and Lowered the Price Target to $ 40 from a previous price target of $42 .

Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Pfizer - Is it time to Sell?

Top Brokerage Firms are advising their investors on Pfizer. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.